PROPERTY SEARCH
PROPERTY SEARCH
ARCHIVED - Covid vaccine developed in Spain enters Phase 2 trials
Hipra plans to produce 400 million vaccines in Spain next year
As the cumulative incidence rate in Spain continues to rise and the vaccine campaign makes steady but relatively slow progress, the Agency for Medicines and Health Products (AEMPS) has authorised the second stage of clinical trials for the home-grown Covid jab, PHH-1V, developed by the company Hipra.
Announcing the news this week, the Spanish President, Pedro Sanchez, said that the progress was an “extraordinary” step forward both for science and Spanish society, and added that the development of the vaccine should be a great “reason for the pride of the country”.
Once fully authorised, Hipra plans to produce 400 million doses of the jab during 2022, which has already been shown to provide a powerful immune response against coronavirus. For now, 15 million euros has been allocated for the next phase of clinical trials, which will be carried out throughout 10 Spanish hospitals and involve the participation of 1,000 patients.
Image: Hipra
Sign up for the Spanish News Today Editors Roundup Weekly Bulletin and get an email with all the week’s news straight to your inbox
Special offer: Subscribe now for 25% off (36.95 euros for 48 Bulletins)
OR
you can sign up to our FREE weekly roundup!
Read some of our recent bulletins:
25% Discount Special Offer subscription:
36.95€ for 48 Editor’s Weekly News Roundup bulletins!
Please CLICK THE BUTTON to subscribe.
(List price 3 months 12 Bulletins)
Read more stories from around Spain:
Contact Spanish News Today: Editorial 966 260 896 /
Office 968 018 268
